Rinat
Rinat Abdrashitov, Toronto CA
Patent application number | Description | Published |
---|---|---|
20150324114 | SYSTEM AND METHOD FOR INTERACTIVE 3D SURGICAL PLANNING AND MODELLING OF SURGICAL IMPLANTS - A method and system for interactive 3D surgical planning are provided. The method and system provide 3D visualisation and manipulation of at least one anatomical feature in response to intuitive user inputs, including gesture inputs. In aspects, fracture segmentation and reduction, screw placement and fitting, and plate placement and contouring in a virtual 3D environment are provided. | 11-12-2015 |
Rinat Ankri, Netanya IL
Patent application number | Description | Published |
---|---|---|
20140194749 | Method and System for Detection of Cancer - A non-invasive and real-time optical method for detection of cancerous cells that includes the steps of optically irradiating an area of a tissue in which targeted nanoparticles are accumulated with a light source outputting an optical signal of ne or more specific wavelengths; identifying cancerous cells by measuring diffusion reflection of the irradiated tissue where the cancerous cells and the nanoparticles are located; and outputting data indicative of the identified cancerous cells. | 07-10-2014 |
20150196200 | NON-INVASIVE METHOD AND SYSTEM FOR DETECTION OF CANCER OR ARTERIAL VASCULAR DISORDERS USING METAL NANOPARTICLES - Non-invasive methods and systems for detection of cancer or arterial vascular disorder involving administering to an individual a composition comprising noble metal nanoparticles that accumulate in a cancerous or injured vascular tissue; optically irradiating an area of a tissue suspected of being a cancerous or injured vascular tissue with a light source outputting an optical signal of at least one wavelength; and measuring diffusion reflection of the area of the irradiated tissue using at least one detector, whereby detection from the measured diffusion reflection of accumulation of the noble metal nanoparticles in this area indicates that the irradiated tissue is a cancerous or injured vascular tissue. | 07-16-2015 |
Rinat Aruh, New York, NY US
Patent application number | Description | Published |
---|---|---|
20100250794 | REMOVABLE ACCESSORY FOR A COMPUTING DEVICE - An accessory computing device or display detachable from another computing device such as a mobile computing device. The accessory computing device displays data from the mobile computing device including notifications relating to electronic mail messages, voice mail messages, stock prices, sports scores, etc. A user interacts with the accessory computing device to control the mobile computing device by, for example, replying to messages, controlling a game executing on the mobile computing device, or silencing a ringer on the mobile computing device. In some embodiments, a plurality of the accessory computing devices interact with the same mobile computing device (e.g., in a multi-player game or device location tracking application executing on the mobile computing device). | 09-30-2010 |
Rinat Bar Shalom, Kfar Bialik IL
Patent application number | Description | Published |
---|---|---|
20160106792 | TREATMENT OF CANCER - Methods of treating colorectal cancer using water extracts derived from | 04-21-2016 |
Rinat Borenshtain, Holon IL
Patent application number | Description | Published |
---|---|---|
20090299418 | CONCURRENT BILATERAL SPG MODULATION - Apparatus ( | 12-03-2009 |
Rinat Lifshiz, Bnei Dror IL
Patent application number | Description | Published |
---|---|---|
20150366979 | POSITIVELY CHARGED POLYSACCHARIDES FOR RNA TRANSFECTION - A complex includes RNA and a positively charged modified polysaccharide selected from starch, amylose, amylopectin, galactan, chitosan, or dextrin. The complex can be formed into a pharmaceutical composition. The complex can be used in methods for RNA transfection, gene therapy and treatment of a disease, disorder or condition. The positively charged modified polysaccharide can be used in connection with RNA transfection into cells. | 12-24-2015 |
Rinat Maksyutov, Novosibirsk Region RU
Patent application number | Description | Published |
---|---|---|
20130011424 | POLYEPITOPE CONSTRUCTS AND METHODS FOR THEIR PREPARATION AND USE - The invention relates to immunogenic polyepitope constructs containing CTL and/or Th epitopes and optimized spacer sequences which improve processing and presentation of the epitopes leading to induction of high level of both CD4+ and CD8+ specific T-cell responses and specific types of cytokines, and high level of protection and therapeutic activity. | 01-10-2013 |
Rinat Moshkovits-Kaptsan, Raanana IL
Patent application number | Description | Published |
---|---|---|
20080287519 | Amorphous eletriptan hydrobromide and process for preparing it and other forms of eletriptan hydrobromide - The invention encompasses amorphous eletriptan hydrobromide, processes for preparing it and pharmaceutical compositions of it. The invention also relates to processes for preparing other forms of eletriptan hydrobromide such as Form α and Form β. | 11-20-2008 |
20090105490 | Polymorphic forms of ramelteon and processes for preparation thereof - An amorphous form of ramelteon is provided, as well as mixtures of amorphous and crystalline ramelteon. Also provided are methods of preparing amorphous ramelteon and mixtures of amorphous and crystalline ramelteon, pharmaceutical compositions comprising amorphous ramelteon and mixtures of amorphous and crystalline ramelteon, and methods of treatment of insomnia using the compositions of the invention. | 04-23-2009 |
20090292025 | Novel crystalline forms of armodafinil and preparation thereof - The invention encompasses crystalline forms of armodafinil, processes for preparing the crystalline forms, and pharmaceutical formulation. | 11-26-2009 |
20100113527 | CRYSTALLINE FORMS OF DEXLANSOPRAZOLE - Provided are crystalline forms of dexLansoprazole, as well as processes for the preparation thereof. | 05-06-2010 |
20120220663 | SOLID FORMS OF ALISKIREN HEMIFUMARATE AND PROCESSES FOR PREPARATION THEREOF - The present invention provides polymorphic forms of aliskiren hemifumarate, and processes for preparation thereof and for the preparation of the amorphous form of aliskiren hemifumarate. The present invention also provides pharmaceutical compositions comprising the aliskiren hemifumarate crystalline forms T1, T3 or T4, T5, T6, T7, T8 and at least one pharmaceutically acceptable excipient, and the use of these pharmaceutical compositions in the treatment of hypertension. | 08-30-2012 |
20130079360 | RALTEGRAVIR SALTS AND CRYSTALLINE FORMS THEREOF - The present invention includes new salts of Raltegravir and crystalline forms thereof, pharmaceutical compositions containing the salts or crystalline forms, methods of using the salts or crystalline forms or the compositions to treat HIV infection or to prepare medicament for treating HIV infection, and a process for preparing Raltegravir potassium. | 03-28-2013 |
20130096147 | Raltegravir Salts and Crystalline Forms Thereof - The present invention includes new salts of Raltegravir and crystalline forms thereof, pharmaceutical compositions containing the salts or crystalline forms, methods of using the salts or crystalline forms or the compositions to treat HIV infection or to prepare medicament for treating HIV infection, and a process for preparing Raltegravir potassium. | 04-18-2013 |
20140256755 | Raltegravir Salts And Crystalline Forms Thereof - The present invention includes new salts of Raltegravir and crystalline forms thereof, pharmaceutical compositions containing the salts or crystalline forms, methods of using the salts or crystalline forms or the compositions to treat HIV infection or to prepare medicament for treating HIV infection, and a process for preparing Raltegravir potassium. | 09-11-2014 |
Rinat Nigmatullin, Nottinghamshire GB
Patent application number | Description | Published |
---|---|---|
20100216908 | Antimicrobial Polymer Nanocomposites - A method of preparing a polymer nanocomposite having antimicrobial properties, comprises (i) contacting a polymeric antimicrobial agent with a clay to form an organoclay; and (ii) subsequently dispersing the organoclay in a polymeric matrix. Polymer nanocomposites prepared by the method of the invention are not prone to leaching of the polymeric antimicrobial agent from the composite, and have many applications. | 08-26-2010 |
Rinat Ran-Ressler, Ithaca, NY US
Patent application number | Description | Published |
---|---|---|
20100298433 | BRANCHED CHAIN FATTY ACIDS FOR PREVENTION OR TREATMENT OF GASTROINTESTINAL DISORDERS - The present invention is directed to a method of preventing or treating a gastrointestinal condition in a subject, that includes administering one or more branched chain fatty acid to the subject under conditions effective to prevent 5 or treat the gastrointestinal condition in the subject. The present invention is also directed to methods of promoting gastrointestinal health in a subject and propagation of probiotic organisms. Also disclosed is a formulation which includes one or more branched chain fatty acid and an aqueous phase emulsified with the one or more branched chain fatty acids, where the formulation includes 10 over 25 wt % of the one or more branched chain fatty acid. | 11-25-2010 |
20160095833 | BRANCHED CHAIN FATTY ACIDS FOR PREVENTION OR TREATMENT OF GASTROINTESTINAL DISORDERS - The present invention is directed to a method of preventing or treating a gastrointestinal condition in a subject, that includes administering one or more branched chain fatty acid to the subject under conditions effective to prevent or treat the gastrointestinal condition in the subject. The present invention is also directed to methods of promoting gastrointestinal health in a subject and propagation of probiotic organisms. Also disclosed is a formulation which includes one or more branched chain fatty acid and an aqueous phase emulsified with the one or more branched chain fatty acids, where the formulation includes over 25 wt % of the one or more branched chain fatty acid. | 04-07-2016 |
Rinat Rotem-Yehudar, Tel Aviv IL
Patent application number | Description | Published |
---|---|---|
20110117085 | MONOCLONAL ANTIBODIES FOR TUMOR TREATMENT - The present invention relates to methods for inhibiting tumor growth, increasing survival of a subject having a tumor and inducing protection against tumor recurrence in a mammal. The methods comprise administering a humanized monoclonal antibody comprising CDR regions derived from the murine monoclonal antibody designated mBAT-1, in combination with at least one chemotherapeutic agent. | 05-19-2011 |
20130022595 | VARIANTS OF HUMANIZED IMMUNOMODULATORY MONOCLONAL ANTIBODIES - The present invention relates to humanized monoclonal antibodies, pharmaceutical compositions that include the same, and use thereof for the treatment of a variety of indications, particularly cancer and immunodeficiency disorders. In particular, the present invention provides modified antibodies or fragments thereof having specific amino acid modifications compared to the humanized monoclonal immunomodulatory antibody termed hBAT-1. | 01-24-2013 |
20140220010 | VARIANTS OF HUMANIZED IMMUNOMODULATORY MONOCLONAL ANTIBODIES - The present invention relates to humanized monoclonal antibodies, pharmaceutical compositions that include the same, and use thereof for the treatment of a variety of indications, particularly cancer and immunodeficiency disorders. In particular, the present invention provides modified antibodies or fragments thereof having specific amino acid modifications compared to the humanized monoclonal immunomodulatory antibody termed hBAT-1. | 08-07-2014 |
20140302032 | MONOCLONAL ANTIBODIES FOR TUMOR TREATMENT - A method of treating a tumor or enhancing survival of a subject having a tumor. The method includes (i) administering to a subject in need thereof an effective amount of a humanized monoclonal antibody or a fragment thereof, wherein the antibody or the fragment thereof has all complementarity determining regions of murine monoclonal antibody BAT (mBAT-1) and a framework region (FR) from an acceptor human immunoglobulin, or modified therefrom; and (ii) administering to the subject an effective amount of at least one chemotherapeutic agent selected from the group consisting of: 5-fluorouracil, cytarabine, oxaliplatin, paclitaxel and combinations thereof. The humanized antibody is administered between 1 and 30 days after commencing chemotherapy or substantially simultaneously or concurrently or according to an overlapping schedule with the at least one chemotherapeutic agent to thereby treat the tumor or enhance the survival of the subject having the tumor. | 10-09-2014 |